This CME/CE program is derived from content presented at the ACTRIMS Forum 2022. The educational activity, chaired by Fred D. Lublin, MD, will analyze best practices for incorporating sphingosine 1 phosphate (S1P) therapeutics in treatment plans for patients with multiple sclerosis (MS). The expert faculty will first outline the pathophysiology and specific science of all S1P receptor modulators. Following, current trial data regarding the safety and efficacy of S1P receptor modulators will be analyzed, along with the clinical implications for the multiple sclerosis patient. The faculty will conclude with a discussion of engaging the interprofessional team to create individualized treatment plans to improve patient outcomes and adherence to therapy in the multiple sclerosis landscape.
Neurologists and other healthcare professionals involved in the treatment and management of patients with relapsing multiple sclerosis
Understand multiple sclerosis disease pathophysiology and the specific science of all S1P receptor modulators
Review recent clinical trial data for S1P receptor modulator therapeutic options to treat patients with relapsing forms of multiple sclerosis
Implement individualized treatment strategies that balance safety with efficacy to optimize S1P receptor therapeutic adherence and improve outcomes for patients with MS
Welcome and Introductions
Sphingosine 1 Phosphate Clinical Science Update as a Therapeutic Target for Relapsing Forms of Multiple Sclerosis
Clinical Trial Review of S1P Receptor Modulators for the Treatment of Patients with Relapsing Forms of Multiple Sclerosis
Individualized Treatment Strategies for S1P-Based Therapeutics to Optimize Adherence and Tolerance to Improve Outcomes for Patients with Multiple Sclerosis
| Faculty | Relationship Identified With: |
| Fred D. Lublin, MD (Course Chair) | Consultant/Advisor: Acorda Therapeutics; Actelion Pharmaceuticals US, Inc.; Apitope; Atara Biotherapeutics; Avotres Inc.; Banner Life Sciences; Biogen; Brainstorm Cell Therapeutics; Bristol-Myers Squibb; Celgene Corporation; EMD Serono Inc.; Entelexo Biotherapeutics; Genentech, Inc.; GW Pharmaceuticals; Horizon Therapeutics plc; Immunic Therapeutics; Janssen Global Services, LLC; Jazz Pharmaceuticals; Labcorp; Mapi-Pharma Ltd.; MedDay Pharmaceuticals; Medimmune, LLC; Mylan; Neuralight; Neurogene; Novartis AG; Orion Biotechnology; Receptos; Roche; Sanofi Genzyme; SetPoint Medical; Teva Pharmaceuticals; TG Therapeutics, Inc.; Viela Bio, Inc. Grant/Research Support: Actelion Pharmaceuticals US, Inc.; Biogen; Brainstorm Cell Therapeutics; Novartis AG; Sanofi Genzyme Stock Options: Avotres Inc.; Neuralight Speaker’s Bureau: Sanofi Genzyme |
| Jiwon Oh, MD, PhD | Consultant/Advisor: Alexion Pharmaceuticals; Biogen; Bristol-Myers Squibb; EMD Serono Inc.; Novartis AG; Roche Grant/Research Support: Biogen; EMD Serono Inc.; Roche |
| Stephanie Tankou, MD, PhD | Nothing to disclose |
| Yinan Zhang, MD | Nothing to disclose |
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole McMenamin; Chelsey Benedek and Emma Boring hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour.
AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEUs) of continuing pharmacy education credit (JA4008190-0000-22-005-H04-P).
Clinicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Bristol-Myers Squibb Company.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Bristol-Myers Squibb Company do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
For all CE inquiries or special needs, please contact admin@academiccme.com.
